Early research (Phase 1)Study completedNCT02746081What this trial is testingPhase I Study of BAY1436032 in IDH1-mutant Advanced Solid TumorsWho this might be right forSolid Tumors Bayer 81
Early research (Phase 1)Active Not RecruitingNCT04603001What this trial is testingStudy of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 MutationsWho this might be right forAcute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)Chronic Myelomonocytic Leukemia (CMML)+1 more Eli Lilly and Company 260
Early research (Phase 1)Active Not RecruitingNCT04521686What this trial is testingStudy of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 MutationsWho this might be right forCholangiocarcinomaChondrosarcomaGlioma+1 more Eli Lilly and Company 200
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07507760What this trial is testingOral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML PatientsWho this might be right forAcute Myeloid Leukemia With Gene Mutations PETHEMA Foundation 50
Not applicableStudy completedNCT06181734What this trial is testingIvosidenib (TIBSOVO®) Combined With Azacitidine According to Current SmPCWho this might be right forAcute Myeloid Leukemia (AML) iOMEDICO AG 8
Not applicableLooking for participantsNCT06607302What this trial is testingIvosidenib in Locally Advanced or Metastatic Cholangiocarcinoma With IDH1 R132 Mutation After at Least One Prior Systemic Treatment - an Observational StudyWho this might be right forCholangiocarcinoma iOMEDICO AG 100
Testing effectiveness (Phase 2)Looking for participantsNCT06161974What this trial is testingStudy of Olutasidenib and Temozolomide in HGGWho this might be right forHigh Grade GliomaAstrocytomaAstrocytoma, Grade III+16 more Rigel Pharmaceuticals 60